Jeantet advises Turenne Santé in connection with its acquisition of a minority stake in H.A.C.Pharma to support the company’s development and strengthen its product portfolio
Paris, February 2, 2022– Jeantet advised Turenne Santé in connection with its acquisition of a minority stake in the pharmaceutical company H.A.C. Pharma, via the FPCI (Fonds Professionnel de Capital Investissement, or Professional private equity investment fund) Capital Santé 2, as lead investor, and BNP Paribas Développement. This transaction marks a new stage in the company’s development, as it seeks to continue launching new drugs and accelerate the expansion of its product portfolio.
With over €280 million under management, including more than €185 million for the FPCI Capital Santé 2, Turenne Santé supports healthcare companies in their development and transfer challenges. Turenne Groupe, one of France’s leading private equity firms, has been helping entrepreneurs with their innovation, development and transfer projects for more than 20 years.
H.A.C.Pharma is a pharmaceutical laboratory within the meaning of the French public health code. Since 2007, it has built up a portfolio of pharmaceutical products, which it makes available in France but also for certain molecules in Europe. As a recognized partner of the hospital sector, H.A.C.Pharma provides therapeutic solutions adapted to patients’ needs and health professionals’ expectations. H.A.C.Pharma strives to achieve this goal and to maintain the availability of vital and tested drugs on the market.
Jeantet (Turenne Santé’s legal counsel): Thierry Brun (partner), Maxime Brotz (Counsel), Maria Plakci and Pak-Hang Li (associates).
H.A.C.Pharma was advised by Dentons and Rothschild & Co.